Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | GSR | P00390 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10859843 | 0.90 | PDCD1 (0.53) | PDCD1CD274GSRSMN1; SMN2CHRM2 | |
| SCHEMBL12972118 | 0.81 | MC4R (0.54) | CYP1A2CYP2D6CYP2C19CHRM2VSIR | |
| SCHEMBL7023370 | 0.81 | ENPP2 (0.47) | PDCD1CD274SMN1; SMN2CHRM2VSIR | |
| SCHEMBL13253641 | 0.81 | MEN1 (0.47) | CYP1A2CYP2D6CYP2C19CHRM2 | |
| SCHEMBL14492270 | 0.81 | PDCD1 (0.54) | PDCD1CD274GSRSMN1; SMN2VSIR | |
| SCHEMBL13918962 | 0.81 | BCHE (0.54) | PDCD1CD274GSRSMN1; SMN2VSIR | |
| SCHEMBL8252697 | 0.80 | L3MBTL1 (0.56) | PDCD1CD274POLBCYP1A2CYP2D6 | |
| SCHEMBL12956919 | 0.80 | PARP1 (0.43) | CYP1A2CYP2D6CYP2C19CHRM2LMNA | |
| SCHEMBL30821501 | 0.80 | GAA (0.53) | PDCD1CD274SMN1; SMN2VSIR | |
| SCHEMBL20428086 | 0.80 | CYP1A2 (0.69) | CYP1A2CYP2D6CYP2C19SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | PDCD1 1475/4885CD274 2361/4885POLB 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.